Neurosymbolic Loon AI® · Peer-reviewed · Independently validated

Regulatory-grade agentic AI for HTA, HEOR and market access

Automate systematic evidence synthesis, optimise value dossiers, and forecast payer decisions — with calibrated confidence that routes the rare uncertain decision to human review.

See the evidence

Evidence that lands.

99.0%SensitivityTitle & abstract screening with ~5% confidence-guided review — Value in Health (ISPOR), 2025 100%Extraction truthfulnessIndependent Cochrane benchmark — PAS, 2026 98.9%Workload reductionValidated independently by the BC Neonatal Cochrane group 96.8%High-confidence accuracyReimbursement forecasting, stratified by Strength of Mandate — medRxiv, 2026

Approved therapies wait 2–5 years for reimbursement.Patients are left waiting for them.

Biopharma loses an estimated $33.5 billion annually to reimbursement delays — evidence work that consumes thousands of expert hours per submission, per jurisdiction.

Loon builds the decision infrastructure that compresses this cycle: scientifically validated agentic AI that takes teams from literature search to payer-ready value evidence, and from reactive paperwork to predictive market access.

Two platforms

One integrated evidence-to-value lifecycle

Loon Lens™

Confidence-calibrated AI systematic literature review

Automates the systematic review process from deduplication, study classification, and screening through study mapping, data extraction, and quality assessment. Screen 100,000+ records in a single pass — no pre-labelling, no pre-training, no fine-tuning.

One-shot extraction from tables, figures, and text — harmonised across studies, no caps
Automatic PRISMA 2020 flowchart, study mapping, and per-datapoint provenance
Any study design or review type — treatment effects, prognostic, cost-effectiveness, qualitative

99.0% sensitivity99.1% specificity100% extraction truthfulness

Loon Lens™ — confidence-calibrated AI systematic literature review, from eligibility criteria to data extraction

Loon Waters™

Value simulation, reimbursement and conditions forecasting

Connects clinical evidence to downstream value and coverage decisions. Monte Carlo Committee Simulation models how payer committees deliberate — anticipating outcomes, conditions, restrictions, and coverage requirements before filing.

Forecast specific reimbursement conditions before committee review
Stress-test value dossiers and submission strategies across jurisdictions simultaneously
Quantify how evidence, price, and ICER changes affect HTA deliberations

95.2% sensitivity97.6% precision96.4% F1

Loon Waters™ — drug reimbursement forecasting and HTA committee modelling

The complete evidence lifecycle

Loon Lens™Search & screenFrom eligibility criteria and citations to screened evidence

Loon Lens™Extract & synthesiseOne clean, harmonised dataset with full provenance

Loon Waters™Simulate & forecastPayer-ready value evidence and de-risked submissions

Together, Loon Lens™ and Loon Waters™ take teams from literature search through to payer-ready value evidence — reducing bottlenecks, preserving data integrity, and compressing the entire evidence cycle.

Calibrated confidence

The only AI that knows when it is uncertain

Every Loon AI® decision carries a calibrated confidence score. Uncertain decisions — typically under 6% — are automatically routed to targeted human review, so teams review only what needs review, not everything or nothing.

Confidence-guided review of just ~5% of records raised precision from 63% to 89.9% and specificity to 99.1%, with 99.0% sensitivity and 99.0% accuracy — validated across 3,796 citations from 8 CDA-AMC reviews.

Specialised agentsScreen, reason, challenge, extract, and adjudicate decisions independently

Mathematical guardrailsNeurosymbolic architecture ensures reliability and full decision transparency

Flexible workflowsAI + human, AI-only, or human-only — masked or open review frameworks

Services

AI-enabled services for HEOR, HTA & market access

Alongside the platforms, Loon's team of drug reimbursement experts, epidemiologists, and HEOR scientists delivers full evidence engagements — as SaaS, tech-enabled services, or fully traditional service, whichever fits your workflow.

Evidence synthesis: SLR, LSR, ITCPeer-reviewed agentic AI conducting HTA-grade (living) systematic literature reviews, meta-analyses, and ITCs (NMA, MAIC, ML-NMR) with efficiency.

ITC feasibility & network evidenceDefensible feasibility studies and NMAs quantifying relative effectiveness when head-to-head evidence is limited — HTA- and JCA-grade evidence at speed.

EU JCAs support & PICOs executionRapid HTA-grade living SLR/LSR® — search strategy, screening, extraction, and ITC feasibility for every PICO in scope, with eligibility criteria stress-tested before they land in the dossier.

Market access intel & committee predictionsForecast reimbursement recommendations and conditions, simulate HTA committee deliberations, and get in-depth therapeutic area analysis to optimize launch sequence.

Reimbursement & HTA submission strategyStreamline global HTA submissions with AI-driven insights — reducing time to market, minimizing conditions, and maximizing reimbursement success.

Value dossier: optimization & simsPrepare, assess, optimize, and continuously update your HTA value dossiers to maximize your drug reimbursement potential in each jurisdiction of interest.

Scientific validation

Peer-reviewed. Independently benchmarked.

medRxiv · 2026 · Pre-printMonte Carlo Committee Simulation for predicting drug reimbursement recommendations and conditions95.2% sensitivity detecting "Reimburse with conditions", 97.6% precision, 96.4% F1 — validated on temporally separated data the models could not have memorised.Janoudi et al. · doi.org/10.64898/2026.03.02.26347434 Pediatric Academic Societies · 2026 · PresentedCan agentic AI replicate a Cochrane neonatal systematic review?Independently benchmarked by the BC Neonatal Cochrane group across 1,865 records: 98.9% workload reduction, 94.1% study concordance, 100% data extraction truthfulness.Mitra, Fisher-Huise, et al. · 2026.pas-meeting.org Value in Health (ISPOR) · 2025 · Peer-reviewedValidating Loon Lens 1.0 for autonomous abstract screening and confidence-guided human-in-the-loop workflows98.9% sensitivity and 95.2% specificity in full AI-only mode across 3,796 citations — rising to 99.0% sensitivity, 99.0% accuracy, and 99.1% specificity with confidence-guided review of ~5% of records, exceeding dual-human screening without pre-labelled training data.Janoudi G, et al. · doi.org/10.1016/j.jval.2025.09.008

Loon at ISPOR · Short courseApplied Generative AI for HEOR: Advanced ArchitecturesLoon leads ISPOR's advanced short course on generative AI architectures for HEOR.

Loon at ISPOR · Issue panel, 2025AI Agents and Guardrails in HEORInvited panellist alongside ICER and Bristol Myers Squibb, in a standing-room-only session on the trustworthiness of agentic AI.

Loon at ISPOR · Posters & papersPeer-reviewed contributions across the programmeIncluding autonomous data extraction from clinical study reports, benchmarked against Canada's Drug Agency reports.

All publications

Who uses Loon

Built for every side of the reimbursement table

Pharmaceutical sponsorsAccelerate SLR timelines, strengthen value dossiers, and model reimbursement outcomes before filing — freeing expert teams for submission strategy, not screening.

HTA bodies & payersReview submitted evidence more efficiently with transparent, auditable AI-assisted workflows — confidence-calibrated and fully traceable to source.

CROs & consultanciesDeliver more reviews in less time without growing headcount — peer-reviewed methodological rigour at scale, for every client engagement.

Access & HEOR teamsShift from reactive to predictive reimbursement strategy — anticipate conditions, model objections, and de-risk every payer interaction.

Security & compliance:No training on client dataZero-day retention with all LLM providersGDPR & PIPEDA compliantFAIR & RAISE audit trailsConfigurable data residencyCompliant with ISPOR ELEVATE-AI, NICE & CDA-AMC position statements

Clients

Our clients become our biggest champions

We work with HTA bodies, Fortune 10 healthcare companies, consultancies, and independent researchers alike — and the HEOR professionals who use Loon are the ones who recommend us.